Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) went down by -0.04% from its latest closing price when compared to the 1-year high value of $52.33 and move down -0.35%, while MNTA stocks collected -0.11% of loss with the last five trading sessions. Press Release reported on 08/31/20 that SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Sale of Momenta Pharmaceuticals, Inc. to Johnson & Johnson
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Worth an Investment?
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) The 36 Months beta value for MNTA stocks is at 1.76, while 2 of the analysts out of 11 who provided ratings for Momenta Pharmaceuticals, Inc. stocks as a “buy” while 0 as overweight, 9 rated it as hold and 0 as sell. The average price we get from analysts is $51.00 which is -$1.36 below current price. MNTA currently has a short float of 5.78% and public float of 117.70M with average trading volume of 2.58M shares.
MNTA Market Performance
MNTA stocks went down by -0.11% for the week, with the monthly jump of 61.21% and a quarterly performance of 75.94%, while its annual performance rate touched 328.16%. The simple moving average for the period of the last 20 days is 29.67% for MNTA stocks with the simple moving average of 78.49% for the last 200 days.
Analysts’ Opinion on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Many brokerage firms have already submitted their reports for MNTA stocks, with Cowen repeating the rating for MNTA shares by setting it to “Outperform”. The predicted price for MNTA socks in the upcoming period according to Cowen is $19 based on the research report published on August 3, 2020.
Goldman, on the other hand, stated in their research note that they expect to see MNTA stock at the price of $29. The rating they have provided for MNTA stocks is “Neutral” according to the report published on March 12, 2020.
JP Morgan gave “ Overweight” rating to MNTA stocks, setting the target price at $30 in the report published on January 15, 2020.
MNTA Stocks 43.95% Far from 50 Day Moving Average
After a stumble in the market that brought MNTA to its low price for the period of the last 52 weeks, Momenta Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -0.34% of loss for the given period.
The stock volatility was left at 3.52%, however, within the period of a single month, the volatility rate increased by 0.33%, while the shares surge at the distance of +61.91% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +32.80% upper at the present time.
In the course of the last 5 trading sessions, MNTA went down by -0.11%, which changed the moving average for the period of 200 days to the total of +224.92% of gains for the stock in comparison to the 20-day moving average settled at $41.21. In addition, Momenta Pharmaceuticals, Inc. saw 164.32% in overturn over the period of a single year with a tendency to cut further gains.
MNTA Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Momenta Pharmaceuticals, Inc. (MNTA), starting from FIER IAN, who sold 1,808 shares at the price of $52.17 back on Aug 20. After this action, Rushing now owns 0 shares of Momenta Pharmaceuticals, Inc., valued at $94,323 with the latest closing price.
Gutierrez-Ramos Jose-Carlos, the Director of Momenta Pharmaceuticals, Inc., sold 10,000 shares at the value of $52.09 during a trade that took place back on Aug 19, which means that Gutierrez-Ramos Jose-Carlos is holding 0 shares at the value of $520,900 based on the most recent closing price.
MNTA Stock Fundamentals
The current profitability levels are settled at -1133.30 for the present operating margin. The net margin for Momenta Pharmaceuticals, Inc. stands at -1215.25. Total capital return value is set at -56.64, while invested capital returns managed to touch -61.08. Equity return holds the value -58.60%, with -43.20% for asset returns.
Based on Momenta Pharmaceuticals, Inc. (MNTA), the company’s capital structure generated 8.75 points for debt to equity in total, while total debt to capital is set at the value of 8.04.
The value for Enterprise to Sales is 61.93 with debt to enterprise value settled at 0.03. The receivables turnover for Momenta Pharmaceuticals, Inc. is 2.46 with the total asset turnover at the value of 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.08.